Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million 2024 expected Total Revenue...

Related Keywords

Canada ,United States ,Joshua Higa ,Emild Kakkis ,Carolyn Wang ,Ultragenyx Pharmaceutical Inc ,Exchange Commission ,Linkedin ,Contacts Ultragenyx Pharmaceutical Inc ,Nasdaq ,Total Revenue ,Healthcare Conference ,Cash Position ,Operations Guidance ,Osteogenesis Imperfecta ,Angelman Syndrome ,Wilson Disease ,Ornithine Transcarbamylase ,Looking Statements ,Private Securities Litigation Reform Act ,Kyowa Kirin ,Quarterly Report ,Investor Relations ,Markets ,